<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278469</url>
  </required_header>
  <id_info>
    <org_study_id>GCX-BCT-06</org_study_id>
    <nct_id>NCT04278469</nct_id>
  </id_info>
  <brief_title>Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy</brief_title>
  <official_title>A Prospective, Randomized, Comparative Study to Evaluate Efficacy of Anticancer Chemotherapy in Predicting Prognosis and Determining Chemotherapy Method in Early Hormone Receptor-positive Breast Cancer Patients With Clinicopathological High Risk and GenesWell™ BCT Low Risk at Multi-center in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gencurix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gencurix, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, comparative study to evaluate efficacy of anticancer chemotherapy
      in predicting prognosis and determining chemotherapy method in early Hormone
      Receptor-positive breast cancer patients with clinicopathological high risk and GenesWell™
      BCT low risk at multi-center in Korea
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>10-year distant metastasis free survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>To evaluate 10-year distant metastasis free survivals according to adjuvant chemotherapy in patients with clinical high and genomic low risk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>To evaluate 10-year disease free survivals and overall survivals according to adjuvant chemotherapy in patients with clinical high and genomic low risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>To evaluate 10-year disease free survivals and overall survivals according to adjuvant chemotherapy in patients with clinical high and genomic low risk</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Early Hormone Receptor-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without chemotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy Drugs, Cancer</intervention_name>
    <description>Clinical high and genomic low Hormone Receptor-positive early breast cancer patients with or without adjuvant chemotherapy</description>
    <arm_group_label>Patients with chemotherapy</arm_group_label>
    <other_name>GenesWell™ BCT (analysis genomic risk)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult women aged 19-80 at screening

          2. Histologically invasive carcinoma

          3. Hormone receptor positive (Estrogen, ER+ and/or Progesterone, PR+)

          4. Human epidermal growth factor receptor 2 negative (HER2-)

          5. Axillary lymph node assessment: pN0 or pN1

          6. Tumor size≥0.5cm

          7. Clinical high risk (based on modified Adjuvant! Online)

          8. Patients who agree to genetic testing

          9. Patients who have adequate organ function

         10. Genomic low risk (based on GenesWell BCT)

         11. De novo primary cancer

         12. Patients how performed surgery with curative aim

         13. Patients who have provided written informed consent themselves

        Exclusion Criteria:

          1. Hormone receptor negative (Estrogen, ER- and Progesterone, PR-)

          2. Human epidermal growth factor receptor 2 positive (HER2+)

          3. Axillary lymph node assessment: pN2 or pN3

          4. Patients who are received chemotherapy prior to operation

          5. Patients who are received radiotherapy prior to operation

          6. Tumor size&lt;0.5cm

          7. Clinical low risk

          8. FFPE tumor sample is not available

          9. Patients with following conditions:

               -  Patient with chronic liver disease

               -  Patient with cerebrovascular disease

               -  Patient with chronic mental disorder

               -  Pregnant women, women of childbearing potential or lactating women

         10. Patients who are deemed inappropriate as study participants by investigators

         11. Patients with recurrent breast cancer or treatment history of breast cancer

         12. Patients who have not undergone surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jungeun Ma, master</last_name>
    <phone>010-7346-2841</phone>
    <phone_ext>82</phone_ext>
    <email>masecret1015@gencurix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jungeun Ma</last_name>
      <phone>010-7346-2841</phone>
      <phone_ext>82</phone_ext>
      <email>masecret1015@gencurix.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

